The center of the investigation is whether or not the proper amount of the active ingredient was contained in the product and if the shelf life had been properly labeled according to the standards set forth by the FDA. There are efforts being made to group together on inspections with other countries as well. Both Australia and the UK are also working with the FDA to jointly inspect drug factories in both China and India. 
The investigation process is in the process. We already had the one nightmare in China in the news with the recent heparin story whereby an economic decision was slated to be at the room of the problem, and hopefully this is not another repeat in the same direction to keep costs down, and the manufacturer is fully cooperating with the FDA. BD
The United States Food and Drugs Administration has filed a complaint against Indian drugmaker Ranbaxy Laboratories Ltd with a local court, saying that the quality of drugs made at one of its domestic plants is poor, according to a person familiar with the matter. Ranbaxy, however, defended itself saying the court has not initiated any proceedings against the company. "Ranbaxy strongly denies these allegations contained in the motion," said a company spokesperson.
0 comments :
Post a Comment